Article (Scientific journals)
Midterm clinical outcome following Edwards SAPIEN or Medtronic Corevalve transcatheter aortic valve implantation (TAVI): Results of the Belgian TAVI registry.
Collas, Valerie M.; Dubois, Christophe; LEGRAND, Victor et al.
2015In Catheterization and Cardiovascular Interventions, 86 (3), p. 528-35
Peer Reviewed verified by ORBi
 

Files


Full Text
Collas_et_al-2015-Catheterization_and_Cardiovascular_Interventions.pdf
Publisher postprint (188.17 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
aortic stenosis; registry; transcatheter aortic valve implantation (TAVI); valvular heart disease
Abstract :
[en] OBJECTIVE: To assess midterm (3 years) clinical outcomes of transcatheter aortic valve implantation (TAVI) in Belgium using the Edwards SAPIEN valve or the Medtronic CoreValve transcatheter heart valve (THV). BACKGROUND: Medium and long term follow-up data of both THVs are still relatively scarce, although of great clinical relevance for a relatively new but rapidly expanding treatment modality. Therefore, reporting mid- and long term clinical outcome data, coming from large "real world" national registries, remains contributive. METHODS: Between December 2007 and March 2012, 861 "real world" patients who were not candidates for surgical aortic valve replacement as decided by the local heart teams, underwent TAVI at 23 sites. Eleven sites exclusively used SAPIEN THV (n = 460), while 12 exclusively used CoreValve THV (n = 401). Differences in clinical outcomes by valve system were assessed, according to access route and baseline EuroSCORE risk profile (<10%: low, 10-20%: intermediate and >20%: high risk). RESULTS: Overall cumulative survival at 3 years was 51% for SAPIEN vs. 60% for CoreValve (P = 0.021). In transfemorally treated patients, SAPIEN and CoreValve had similar survival at 3 years for each of the baseline EuroSCORE cohorts (low risk: 72% vs. 76%, P = 0.45; intermediate risk: 62% vs. 59%, P = 0.94; high risk: 48% vs. 53%, P = 0.65). CONCLUSION: Cumulative midterm 3 year survival after transfemoral TAVI in "real world" patients refused for surgery with similar baseline EuroSCORE risk profile is not different between SAPIEN or CoreValve.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Collas, Valerie M.
Dubois, Christophe ;  Centre Hospitalier Universitaire de Liège - CHU > Cardiologie
LEGRAND, Victor ;  Centre Hospitalier Universitaire de Liège - CHU > Cardiologie
Kefer, Joelle
De Bruyne, Bernard
Dens, Jo
Rodrigus, Inez E.
Herijgers, Paul
Bosmans, Johan M.
Language :
English
Title :
Midterm clinical outcome following Edwards SAPIEN or Medtronic Corevalve transcatheter aortic valve implantation (TAVI): Results of the Belgian TAVI registry.
Publication date :
2015
Journal title :
Catheterization and Cardiovascular Interventions
ISSN :
1522-1946
eISSN :
1522-726X
Publisher :
John Wiley & Sons, Hoboken, United States - New York
Volume :
86
Issue :
3
Pages :
528-35
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
(c) 2015 Wiley Periodicals, Inc.
Available on ORBi :
since 14 February 2016

Statistics


Number of views
217 (6 by ULiège)
Number of downloads
234 (3 by ULiège)

Scopus citations®
 
14
Scopus citations®
without self-citations
13
OpenCitations
 
12

Bibliography


Similar publications



Contact ORBi